[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Forner, A., Reig, M. and Bruix J. (2018) Hepatocellular Carcinoma. Lancet, 391, 1301-1314.
https://doi.org/10.1016/S0140-6736(18)30010-2
|
[3]
|
Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. https://doi.org/10.1038/s41575-019-0186-y
|
[4]
|
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., et al. (2020) Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 9, 682-720. https://doi.org/10.1159/000509424
|
[5]
|
Park, J.W., Chen, M., Colombo, M., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International, 35, 2155-2166. https://doi.org/10.1111/liv.12818
|
[6]
|
Ando, E., Tanaka, M., Yamashita, F., Kuromatsu, R., Yutani, S., Fukumori, K., et al. (2002) Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Analysis of 48 Cases. Cancer, 95, 588-595. https://doi.org/10.1002/cncr.10694
|
[7]
|
Kudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Ima,i Y., et al. (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update By the Liver Cancer Study Group of Japan. Liver Cancer, 3, 458-468. https://doi.org/10.1159/000343875
|
[8]
|
Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., et al. (2013) Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/leucovorin versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. Journal of Clinical Oncology, 31, 3501-3508.
https://doi.org/10.1200/JCO.2012.44.5643
|
[9]
|
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., et al. (2018) Hepatic Arterial Infusion of Oxaliplatin Plus Fluorouracil/leucovorin vs. Sorafenib for Advanced Hepatocellular Carcinoma. Journal of Hepatology, 69, 60-69.
https://doi.org/10.1016/j.jhep.2018.02.008
|
[10]
|
He, M.K., Le, Y., Li, Q.J., Yu, Z.S., Li, S.H., Wei, W., et al. (2017) Hepatic Artery Infusion Chemotherapy Using MFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, Article No. 83.
https://doi.org/10.1186/s40880-017-0251-2
|
[11]
|
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版) [J]. 中国实用外科杂志, 2021, 41(6): 618-632.
|
[12]
|
Ahn, Y.E., Suh, S.J., Yim, H.J., Seo, Y.S., Yoon, E.L., Kim, T.H., et al. (2021) Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver, 15, 284-294. https://doi.org/10.5009/gnl19367
|
[13]
|
Choi, J.H., Chung, W.J., Bae, S.H., Song, D.S., Song, M.J., Kim, Y.S., et al. (2018) Randomized, Prospective, Comparative Study On the Effects and Safety of Sorafenib Vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. https://doi.org/10.1007/s00280-018-3638-0
|
[14]
|
Abdelmaksoud, A.H.K., Abdelaziz, A.O., Nabeel, M.M., Hamza, I., Elbaz, T.M., Shousha, H.I., et al. (2021) Hepatic Arterial Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: A Case-Control Study. Clinical Radiology, 76, 709.E1-709.E6. https://doi.org/10.1016/j.crad.2021.03.022
|
[15]
|
中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版) [J]. 肝癌电子杂志, 2021, 8(2): 6-15.
|
[16]
|
李建基, 杨哲, 黄赞松. 原发性肝癌分子靶向治疗基础与临床研究进展[J]. 世界华人消化杂志, 2019, 27(10): 643-650.
|
[17]
|
Poggi, G., Montagna, B., Melchiorre, F., Quaretti, P., Delmonte, A., Riccardi, A., et al. (2011) Hepatic Intra-Arterial Cetuximab in Combination with 5-Fluorouracil and Cisplatin as Salvage Treatment for Sorafenib-Refractory Hepatocellular Carcinoma. Anticancer Research, 31, 3927-3933.
|
[18]
|
Nagai, H., Mukozu, T., Ogino, Y.U., Matsui, D., Matsui, T., Wakui, N., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2277.
|
[19]
|
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., et al. (2019) Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[20]
|
都亚薇, 张宁宁, 陆伟. 肝癌免疫治疗的研究现状及展望[J]. 实用肿瘤杂志, 2021, 36(5):393-398.
|
[21]
|
He, M.K., Liang, R.B., Zhao, Y., Xu, Y.J., Chen, H.W., Zhou, Y.M., et al. (2021) Lenvatinib, Toripalimab, Plus Hepatic Arterial Infusion Chemotherapy versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma. Therapeutic Advances in Medical Oncology, 13, Article ID: 17588359211002720. https://doi.org/10.1177/17588359211002720
|
[22]
|
Xu, Y.J., Lai, Z.C., He, M.K., Bu, X.Y., Chen, H.W., Zhou, Y.M., et al. (2021) Toripalimab Combined with Hepatic Arterial Infusion Chemotherapy versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research & Treatment, 20, Article ID: 15330338211063848. https://doi.org/10.1177/15330338211063848
|
[23]
|
Kamiyama, T., Nakanishi, K., Yokoo, H., Tahara, M., Nakagawa, T., Kamachi, H., et al. (2007) Efficacy of Preoperative Radiotherapy to Portal Vein Tumor Thrombus in the Main Trunk or First Branch in Patients with Hepatocellular Carcinoma. International Journal of Clinical Oncology, 12, 363-368. https://doi.org/10.1007/s10147-007-0701-y
|
[24]
|
Kodama, K., Kawaoka, T., Aikata, H., Uchikawa, S., Nishida, Y., Inagaki, Y., et al. (2018) Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Oncology, 94, 215-222.
https://doi.org/10.1159/000486483
|
[25]
|
Byun, H.K., Kim, H.J., Im, Y.R., Kim, D.Y., Han, K.H. and Seong, J. (2019) Dose Escalation by Intensity Modulated Radiotherapy in Liver-Directed Concurrent Chemoradiotherapy for Locally Advanced BCLC Stage C Hepatocellular Carcinoma. Radiotherapy and Oncology, 133, 1-8. https://doi.org/10.1016/j.radonc.2018.12.025
|